Key result
The HAS-BLED score is recommended by international guidelines to estimate individual bleeding risk in atrial fibrillation patients receiving antithrombotic treatment.
This review highlights the importance of evaluating bleeding risk in atrial fibrillation patients on anticoagulation and discusses the use of the HAS-BLED score as recommended by guidelines.
Supports guideline-directed HAS-BLED use in AF; confirms consensus yet leaves comparative validation open.
This issue addresses the evaluation of hemorrhagic risk during antithrombotic treatment in atrial fibrillation patients. It illustrates the relevance of bleeding complications in the management of anticoagulation therapy and demonstrates the size of the problem among patients taking old and novel oral anticoagulant drugs. A survey of the main factors affecting the bleeding risk with pertinent supporting evidence is performed. Finally the paper discusses how to estimate the individual bleeding risk focusing on the HAS-BLED score, whose use is recommended by international guidelines.
No takes yet. Share an insight, caveat, or question.
Fusco et al. (2013) conducted a review in Atrial fibrillation. Antithrombotic treatment and HAS-BLED score was evaluated. The HAS-BLED score is recommended by international guidelines to estimate individual bleeding risk in atrial fibrillation patients receiving antithrombotic treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: